Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study.

Peng-Xiang WangYun-Fan SunKai-Qian ZhouJian-Wen ChengBo HuWei GuoYue YinJun-Feng HuangJian ZhouJia FanTan To CheungXu-Dong QuXin-Rong Yang

Published in: Clinical and translational medicine (2020)

Preoperative CTC status could serve as an indicator for the administration of adjuvant TACE in HCC patients. Adjuvant TACE benefits CTC-positive HCC patients mainly by reducing early recurrence.

Keyphrases

circulating tumor cells
end stage renal disease
early stage
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
cross sectional
circulating tumor
cell free